CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
滤泡性淋巴瘤的 CAR-T 细胞治疗
英文原题：CAR-T Cell Therapy for Follicular Lymphomas.
查看英文原题
CAR-T Cell Therapy for Follicular Lymphomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
滤泡性淋巴瘤是西欧第二常见的淋巴瘤。显著进展已大幅改善FL患者的生存。然而，其中10-20%的患者对标准治疗难治，且大多数将会复发。对多线复发/难治性疾病的滤泡性淋巴瘤患者的治疗是一个高度未满足需求的领域，需要更强效的新治疗。靶向B细胞抗原（如CD19或CD20）的嵌合抗原受体（CAR）-T细胞疗法正成为R/R滤泡性淋巴瘤患者的一种有效治疗，特别是对于那些早期复发且对烷化剂和抗CD20单克隆抗体难治的患者，可在高比例患者中产生高率的持久缓解。
展开英文摘要原文
Follicular lymphoma is the second most diagnosed lymphoma in Western Europe. Significant advancements have considerably improved the survival of FL patients.
However, 10-20% of these patients are refractory to standard treatments, and most of them will relapse. The treatment of follicular lymphoma patients with multiply relapsed or refractory disease represents an area of high-unmet needing new treatments with stronger efficacy.
Chimeric antigen receptor (CAR)-T cell therapy targeting B-cell antigens, such as CD19 or CD20, is emerging as an efficacious treatment for R/R follicular lymphoma patients, particularly for those with early relapse and refractory to alkylating agents and to anti-CD20 monoclonal antibodies, resulting in a high rate of durable responses in a high proportion of patients.
论文信息
- 作者
- Testa U、D'Alò F、Pelosi E、Castelli G、Leone G
- 第一作者单位
- Istituto Superiore di Sanità, Roma.Italy
- 通讯作者单位
- Dipartimento Di Scienze Radiologiche Ed Ematologiche, Università Cattolica Del Sacro Cuore, Roma, Italy.Italy
- 文献类型
- 综述
- 期刊
- Mediterranean journal of hematology and infectious diseases2024
- 原文标识
- PubMed 38223488 · DOI 10.4084/MJHID.2024.012
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →